Methods and compositions for reducing autofluorescence
US-2024209423-A1 · Jun 27, 2024 · US
US9829481B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9829481-B2 |
| Application number | US-201514632475-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 26, 2015 |
| Priority date | Aug 28, 2012 |
| Publication date | Nov 28, 2017 |
| Grant date | Nov 28, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The instant invention relates to novel compounds useful for visualizing cell senescence, their preparation and use. In particular, this invention relates to novel fucose and amino-quinoline derivatives useful as senescence traces and their preparation.
Opening claim text (preview).
What is claimed is: 1. Compound of formula A-L-M (I) in which, A represents wherein, * represents the binding site to the residue represented by L, L represents *Y-(CH 2 ) n - # or wherein, Y is selected from the group consisting of O, N, S, SO and SO 2 , n is an integer from 2 to 6, * represents the binding site to the residue represented by A, and # represents the binding site to the residue represented by M, and M represents a fluorophore, a residue comprising at least one atom selected from the group consisting of 76 Br, 75 Br, 18 F, 13 C and 11 C or a combination thereof, and the salts thereof, the solvates thereof and the solvates of the salts thereof. 2. Compound according to claim 1 , wherein n is 2, 3 or 4. 3. Compound according to claim 1 , wherein M represents a fluorophore. 4. Compound according to claim 3 , wherein the fluorophore is selected from the group consisting of the xanthene derivatives, fluorescein, rhodamine, Oregon green, eosin, and Texas red, the cyanine derivatives, cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine, and merocyanine, the naphthalene derivatives, a dansyl or derivatives thereof, the coumarin derivatives, the oxadiazole derivatives, pyridyloxazole, nitrobenzoxadiazole and benzoxadiazole, the pyrene derivatives, the oxazine derivatives, Nile red, Nile blue and cresyl violet, the acridine derivatives, proflavin, acridine orange and acridine yellow, the arylmethine derivatives, auramine, crystal violet and malachite green, and the tetrapyrrole derivatives, porphin, phthalocyanine and bilirubin. 5. Compound according to claim 1 , wherein M is selected from 76 Br, 75 Br, 18 F, wherein, X is selected from the group consisting of Br, 76 Br, 75 Br, Cl, F and 18 F, R 1 represents hydrogen or (C 1 -C 6 )-alkyl, whereby alkyl is substituted with one to three substituents selected independently from the group consisting of hydroxy, amino, cyano, nitro, halogen, carbonyl, (C 1 -C 4 )-alkoxy, mono (C 1 -C 4 )-alkylamino and di-(C 1 -C 4 )-alkylamino, whereby R 1 represents an optionally substituted (C 1 -C 6 )-alkyl comprising at least one 76 Br, 75 Br, 18 F or 11 C if X is not 76 Br, 75 Br or 18 F, R 2 and R 3 independently from one another represent hydrogen or (C 1 -C 6 )-alkyl, whereby alkyl is substituted with one to three substituents selected independently form the group consisting of, hydroxy, amino, cyano, nitro, halogen, carbonyl, (C 1 -C 4 )-alkoxy, mono (C 1 -C 4 )-alkylamino and di-(C 1 -C 4 )-alkylamino, whereby at least one of R 2 and R 3 represents a (C 1 -C 6 )-alkyl comprising at least one 11 C or being substituted with a residue comprising at least one 76 Br, 75 Br, 18 F or 11 C, and * represents the binding site to the residue represented by L. 6. Medicament comprising a compound according to claim 1 in combination with at least one inert, non-toxic, pharmaceutically suitable excipient.
Aging, e.g. cellular aging · CPC title
with fluorescent label · CPC title
Acyclic or carbocyclic radicals, substituted by hetero rings · CPC title
involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025) · CPC title
with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.